Evidence map›Paper›PMID 42490979›Full record

ArticleFrontiers in pharmacology2026

He Gong, Sixian Chen, Zhuohua Huang, Hong Yuan, Jiang Ma, Xin He

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

He GongSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, China.
Sixian ChenSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, China.
Zhuohua HuangSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, China.
Hong YuanSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, China.
Jiang MaSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, China.
Xin HeSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Methods: Using constituent knock-out/knock-in technology and HPLC fingerprinting, Results: TGT reduced serum creatinine, urea nitrogen, and uric acid levels, improved renal filtration, and restored kidney morphology. Metabolomic and microbiota analyses revealed decreased indole and amino acid derivatives and regulation of Conclusion: TGT exerts renoprotective effects partly by modulating the gut-liver-kidney axis and reducing gut-derived uremic toxins, while alkaloids likely contribute to its toxicity. These findings offer new insights into the safe and effective use of TGT in CKD therapy.

Indexed as

alkaloidchronic kidney diseaseconstituents knock-out/knock-in technologygut-derived uremic toxinstripterygium glycosides tablet

Identifiers

PMID42490979
PMCPMC13375623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.